entertainment -WSS

entertainment

author：entertainment 2025-09-30 22:09:59 - browse：43

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

leisure time

WSS

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Long Covid research funding gets a major boost from NIH

Latigo launches with $135 million for Vertex

ADCs take center stage as promising cancer treatments

FDA clears Verve to begin U.S. study of gene

UnitedHealth, Optum discontinue NaviHealth name

knowledge

entertainment

knowledge

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

https://cbu01.alicdn.com/img/ibank/2017/226/148/4468841622_299359824.220x220xz.jpg

Heart attack and stroke risk calculators need revising

CZI to create biohub to build anti

Supreme Court strikes down use of affirmative action

STAT Boddities: What happens to the brain when we get scared?

How to save PrEP access — and even expand it

STAT Summit: How researchers deal with rejection

explore

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Ebola vaccine can save some who are already sick, per new study

Health tech investors get more selective as pandemic boom fades

Readout Newsletter: Amylyx, Aurinia, and IQVIA

STAT Readout Newsletter: Biotech news today

Roche acquires Telavant from Roivant, adding experimental IBD treatment

focus

explore

leisure time

explore